Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines

Experimental Oncology

Volumn 30, Issue 2, 2008, Pages 129-132

  Valkovskaya, N V ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

ADAM8; Hypoxia; Invasion; Pancreatic cancer

Indexed keywords

MESSENGER RNA; PROTEIN ADAM8;

ARTICLE; CANCER CELL; CANCER INVASION; CELL LINE; CORRELATION ANALYSIS; FATALITY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; MALIGNANT TRANSFORMATION; METASTASIS; PANCREAS CANCER; PATHOGENESIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ADAM PROTEINS; ANOXIA; CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; OXYGEN; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 46749098368     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Vaupel P, Mauer A, Hoeckel M. Tumor hypoxia and malignant progression. Meth Enzymol 2004; 381: 335-54.
2. Tatum JL, Kelloff GJ, Gillies RJ. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82: 699-757.
3. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-39.
4. Pugh ChW, Ratcliff PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med 2003; 9: 677-84.
5. Chaudary N, Hill RP. Hypoxia and metastasis. Clin Cancer Res 2007; 13: 1947-9.
6. Zhou J, Schmidt T, Schnitzer S, Bruene B. Tumor hypoxia and cancer progression. Cancer Lett 2006; 237: 10-21.
7. Ghaneh P, Smith R, Tudor-Smith C, et al. Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2008; 34: 297-305.
8. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48: 919-22
9. Buchler P, Reber HA, Lavey RS, et al. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res 2004; 120: 295-303.
10. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004; 10: 2299-306.
11. Vihinen P, Kähäri V-M. Matrix metalloproteinases in cancer: Prognostic markers and therapeutic tagets. Int J Cancer 2002; 99: 157-66.
12. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
13. Osinsky S, Ganusevich I, Bubnovskaya L, et al. Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis. Exp Oncol 2005; 27: 202-5.
14. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995; 131:275-8.
15. Schlomann U, Wildeboer D, Webster A, et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002; 277: 48210-9.
16. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10: 8363-70.
17. Roemer A, Schwettmann L, Jung M, et al. The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol 2004; 172: 2162-6.
18. Fritzsche FR, Jung M, Xu C, et al. ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch 2006; 449: 628-36.
19. Wildeboer D, Naus S, Amy Sang QX, et al. Metalloproteinase disintegrins ADAM8 and ADAM 19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol 2006; 65: 516-27.
20. Yamada D, Ohuchida K, Mizumoto K, et al. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res 2007; 27: 793-9.
21. Grutzmann R, Luttges J, Sipos B, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004; 90: 1053-8.
22. Ringel J, Jesnowski R, Moniaux N, et al. Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res 2006; 66: 9045-53.
23. Amour A, Knight CG, English WR, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002; 524: 154-8.
24. Valkovskaya N, Kayed H, Felix K, et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cellul Mol Med 2007; 11: 1162-74.
25. Erkan M, Kleeff J, Esposito I, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005; 24:4421-32.
26. Arribas J, Bech-Serra JJ, Santiago-Josefat B. AD-AMs, cell migration and cancer. Cancer Metastasis Rev 2006; 25: 57-68.
27. Marshall AJ, Rattray M, Vaughan PF. Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM 10 and TACE, without altering their mRNA levels. Brain Res 2006; 1099: 18-24.
28. Sung SY, Kubo H, Shigemura K, et al. Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells. Cancer Res 2006; 66: 9519-26.